John Feore is a Senior Director of Health and Reimbursement Policy. In his role, John provides strategic advice on health policy and reimbursement matters and representing clients before the Centers for Medicare and Medicaid Services (CMS) and other key stakeholders. He advises biopharmaceutical companies and trade associations on health policy matters relating to federal healthcare programs, such as Medicare fee-for-service, Medicare Advantage, Part D, 340B, and Medicaid. John regularly speaks before patient and pharmaceutical audiences on topics related to federal health policy, particularly drug pricing, rare and orphan diseases, and access to innovative therapies.

Through his role at Kimbell & Associates, John serves as the Director of Health Policy and Advocacy for the Institute for Gene Therapies (IGT), a non-profit advocacy organization launched in 2020 to help address coverage, access, and reimbursement challenges surrounding gene therapies. He also serves as a Council Member for the Virginia Rare Disease Council.

Prior to joining the firm in 2020, John was an Associate Principal in Avalere's Center for Healthcare Transformation, where he worked closely with life sciences companies, providers, suppliers, and trade associations on issues related to Medicare and Medicaid, federal health policy, and drug pricing and reimbursement among others.

John previously was a Senior Managing Associate at Dentons US LLP, where he counseled clients on the impact of federal health policy, including the Affordable Care Act (ACA) and Medicare Modernization Act (MMA).

John has a Juris Doctor from the Catholic University of America Columbus School of Law and a Bachelor of Arts in Political Science from Boston College. He lives in Arlington, Virginia with his wife and three sons.

​

Back to Team